Of these, tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR) mutated or anaplastic lymphoma kinase (ALK) translocated NSCLC were already successfully implemented into the clinical setting. This evidence concerns the gene ALK and non-small cell lung carcinoma.